Belgian soft mist inhaler company Softhale has announced the appointment of Nevan Charles Elam to its board of directors. Currently Chairman and CEO of Rezolute, Elam was formerly Senior VP and Head of the Pulmonary Business Unit at Nektar Therapeutics. He has served on the boards of Nektar spin-out Pearl Therapeutics and Aerogen, and currently serves on the board of inhaled drug developer Savara.
Softhale Chairman of the Board Frank Pieters commented, “We are delighted to welcome Nevan on our board. His rich background in management, operations, consulting, finance, and corporate law in combination with long term experiences in executive roles in pharmaceutical and medical device companies will broaden the competencies of our board and support further development of the company.”
Elam said, “I am excited to join Softhale’s board, as I enjoy working with innovative companies that have the potential transform markets and improve patient care. I believe that Softhale has the right combination of a robust device platform along with an experienced and proven management team.”
Read the Softhale press release.
